Among them, PD-1/PD-L1 inhibitors are representative and have improved the clinical efficacy of NSCLC treatment to a certain extent (Herbst et al., 2016; Brahmer et al., 2017; Mok et al., 2019). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.